SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2744-2748. Prepublished online as a Blood First Edition Paper on June 26, 2007; DOI 10.1182/blood-2007-03-078592. This Article Full Text (PDF) All Versions of this Article: blood-2007-03-078592v1 110/7/2744    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kahl, C. Articles by Storb, R. Search for Related Content PubMed PubMed Citation Articles by Kahl, C. Articles by Storb, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 16, 2007 Accepted June 4, 2007 Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Christoph Kahl, Barry E Storer, Brenda M. Sandmaier, Marco Mielcarek, Michael B Maris, Karl G Blume, Dietger Niederwieser, Thomas R Chauncey, Stephen J Forman, Edward Agura, Jose F Leis, Benedetto Bruno, Amelia Langston, Michael A Pulsipher, Peter A McSweeney, James C Wade, Elliot Epner, Finn Bo Petersen, Wolfgang A Bethge, David G Maloney, and Rainer Storb* Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States University of Washington School of Medicine, Seattle, WA, United States BMT, Rocky Mountain Blood and Marrow Transplant Program, Denver, CO, United States BMT, Stanford University, Stanford, CA, United States Department of Medicine, University of Leipzig, Leipzig, Germany Veterans Affairs Puget Sound Health System, Seattle, WA, United States BMT, City of Hope National Medical Center, Duarte, CA, United States BMT, Baylor University, Dallas, TX, United States BMT, Oregon Health and Science University, Portland, OR, United States BMT, University of Torino, Torino, Italy BMT, Emory University, Atlanta, GA, United States BMT, University of Utah Health Sciences Center, Salt Lake City, UT, United States BMT, Medical College of Wisconsin, Milwaukee, WI, United States Blood and Marrow Outpatient Clinic, Intermountain Healthcare - LDS Hospital, Salt Lake City, UT, United States BMT, University Hospital Tuebingen, Tuebingen, Germany * Corresponding author; email: rstorb{at}fhcrc.org. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignancies depends on graft-versus-tumor effects for eradication of cancer. Here, we estimated relapse risks according to disease characteristics. Between 1997 and 2006, 834 consecutive patients (median age, 55; range, 5-74 years) received related (n=498) or unrelated (n=336) HCT after 2 Gy total body irradiation alone (n=171), or combined with fludarabine (90 mg/m2; n=663). Relapse rates per patient year (PY) at risk, corrected for follow-up and competing non-relapse mortality, were calculated for 29 different diseases and stages. The overall relapse rate per PY was 0.36. Patients with CLL and MM in remission (CR), low-grade or mantle cell NHL (CR + PR), and high-grade NHL-CR had the lowest rates (0.00-0.24; low risk). In contrast, patients with advanced myeloid and lymphoid malignancies had rates of >0.52 (high risk). Patients with lymphoproliferative diseases not in CR (except Hodgkin lymphoma and high grade NHL) and myeloid malignancies in CR had rates of 0.26-0.37 (standard risk). In conclusion, patients with low-grade lymphoproliferative disorders experienced the lowest relapse rates, whereas patients with advanced myeloid and lymphoid malignancies had high relapse rates after nonmyeloablative HCT. The latter might benefit from cytoreductive treatment before HCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P. J. Martin, B. E. Storer, S. D. Rowley, M. E. D. Flowers, S. J. Lee, P. A. Carpenter, J. R. Wingard, P. J. Shaughnessy, M. P. DeVetten, M. Jagasia, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease Blood, May 21, 2009; 113(21): 5074 - 5082. [Abstract] [Full Text] [PDF] A. Bashey, B. Medina, S. Corringham, M. Pasek, E. Carrier, L. Vrooman, I. Lowy, S. R. Solomon, L. E. Morris, H. K. Holland, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood, February 12, 2009; 113(7): 1581 - 1588. [Abstract] [Full Text] [PDF] K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al. Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2009; 27(3): 426 - 432. [Abstract] [Full Text] [PDF] M. Yanada, G. Garcia-Manero, G. Borthakur, F. Ravandi, H. Kantarjian, and E. Estey Relapse and death during first remission in acute myeloid leukemia Haematologica, April 1, 2008; 93(4): 633 - 634. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020